%0 Journal Article %A Jeffrey M. McManus %A Navin Sabharwal %A Peter Bazeley %A Nima Sharifi %T A common androgen synthesis variant is associated with COVID susceptibility %D 2020 %R 10.1101/2020.08.27.20183004 %J medRxiv %P 2020.08.27.20183004 %X A sex discordance in COVID exists, with males disproportionately affected1-3. More broadly, sex differences in infectious and inflammatory processes are well known, with women tending to mount stronger immune responses than men4,5. Although there is evidence that sex hormone signaling is immunomodulatory6-8, including downregulation of immune/inflammatory responses by androgens9, the existence of numerous other physiologic differences between the sexes leads to great uncertainty in attributing worse infectious disease outcomes in men to androgen signaling. No definitive genetic data exist to support androgen-mediated immune suppression for viral susceptibility, nor for adrenal androgens. Here we show an association between inheritance of the common adrenal-permissive missense-encoding variant HSD3B1(1245C), that enables androgen synthesis from adrenal precursors10, and susceptibility to COVID. The adrenal-permissive HSD3B1(1245C) has previously been linked to suppression of inflammation in severe asthma11. In analysis of COVID test results from the UK Biobank, we show that in older (≥ 70 years of age) subjects, the adrenal-permissive variant is associated with a greater chance of being COVID-positive. The effect increases with the number of HSD3B1(1245C) alleles inherited and is greater in females such that increasing androgen synthesis confers risk approaching males. Our study suggests that a common androgen synthesis variant regulates immune susceptibility to COVID infection as well as potentially other immune and inflammatory processes.Competing Interest StatementCleveland Clinic has a patent on HSD3B1 in prostate cancer.Funding StatementThis work was supported in part with grants from the National Cancer Institute (R01CA172382, R01CA190289, and R01CA236780) and the Prostate Cancer Foundation (to NS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study from UK Biobank and related oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available per regulations of UK Biobank. %U https://www.medrxiv.org/content/medrxiv/early/2020/09/01/2020.08.27.20183004.full.pdf